RANIDO: A phase III clinical trial of racotumomab-alum or nimotuzumab versus docetaxel in advanced non-small cell lung cancer patients

Autor:	Amparo Macías, M. Hernandez, Elia Neninger, Anet Valdes, Yoana Flores, Ivis Mendoza, Rosa Maria Amador, Ramón Ortiz, Eduardo Santiesteban, Mayte Robaina, Tania Crombet, Ana María Vázquez, Soraida Acosta, Pedro Pablo Guerra
Rok vydání:	2014
Předmět:	Oncology Cancer Research medicine.medical_specialty Alum business.industry medicine.medical_treatment Racotumomab Immunotherapy medicine.disease Clinical trial chemistry.chemical_compound Immune system chemistry Docetaxel Internal medicine medicine Nimotuzumab Lung cancer business medicine.drug
Zdroj:	Journal of Clinical Oncology. 32:TPS3111-TPS3111
ISSN:	1527-7755 0732-183X
DOI:	10.1200/jco.2014.32.15_suppl.tps3111
Popis:	TPS3111 Background: Despite extensive research in NSCLC treatment, overall survival remains insufficient. Immunotherapy has become a viable treatment to help the immune system to control or elimina...
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::9c744fbf116e5338b989e136c49f7f8e https://doi.org/10.1200/jco.2014.32.15_suppl.tps3111 Zobrazit plný text záznamu